Updates and Managed Care Considerations for BCMA-Targeted Strategies in Multiple Myeloma

This activity was originally broadcast live as a satellite symposium held in conjunction with AMCP eLearning Days 2022.

Program Description

B-cell maturation antigen (BCMA) has emerged as a therapeutic target for patients with multiple myeloma (MM). Ongoing investigations have focused on developing these agents for use as both monotherapy and in combination regimens. This activity will provide pharmacists with clinical data for BCMA-targeted therapies, including discussion on efficacy and adverse effect management. Managed care pharmacists must consider the future role of agents targeting BCMA in patients with MM and determine clinical eligibility criteria to facilitate patient access to these treatments. Strategies for managed care pharmacists to incorporate pathways in accordance with guideline recommendations, improve healthcare resource utilization, and ensure appropriate use of emerging BCMA-targeted therapies will be presented.

Target audience: Health-system, managed care, oncology, and specialty pharmacists

Type of activity: Application
Release date: May 18, 2022
Expiration date: May 18, 2023

Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Illustrate the mechanism of B-cell maturation antigen (BCMA) as a therapeutic target for multiple myeloma (MM) to better understand the use of these targeted therapies in treatment algorithms
• Identify the place in therapy for BCMA-targeted therapies in MM and the patient populations who may be candidates for treatment
• Analyze strategies for evaluating and developing clinical eligibility criteria for the cost-effective use of BCMA-targeted therapies in the treatment of MM

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-255-H01-P. The activity is available for CE credit through May 18, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Joseph A. Kalis, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:
Speakers Bureau: Oncopeptides, GSK

Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, has the following financial relationships with commercial interests to disclose:
Grant/Research Support: AstraZeneca, Janssen

Consultant: BeiGene

Speakers Bureau: Pfizer

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Dipti Desai, PharmD, MBA, CHCP; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms